As New Jersey’s only NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, provides patients access to the most advanced treatment options including complex surgical procedures, sophisticated radiation therapy techniques, innovative clinical trials, immunotherapy, and precision medicine.
|
|
|
$1.3 Million Awarded to Rutgers Cancer Institute and George Mason University Collaborative
|
|
|
A collaborative effort between Rutgers Cancer Institute of New Jersey and George Mason University has received a $1.3 million U.S. Army Breast Cancer Research Program (BCRP) Breakthrough Award to explore HER2 biomarkers in personalized breast cancer treatments. The work will examine new ways to measure biomarkers of the HER2 protein, which is expressed on breast cancer cells. Shridar Ganesan, MD, PhD, chief of molecular oncology, associate director for translational research, and Omar Boraie Chair in Genomic Science at Rutgers Cancer Institute and professor of medicine and pharmacology at Rutgers Robert Wood Johnson Medical School, is the Rutgers Cancer Institute principal investigator of the project. Learn more
|
|
Surface Testing for SARS-CoV2 in Hematology/Oncology Settings Reveals Negligible Detection
|
|
|
Researchers from Rutgers Cancer Institute of New Jersey evaluated the frequency of SARS-CoV-2 RNA, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. Andrew M. Evens, DO, MSc, FACP, associate director for clinical services and director of the Lymphoma Program at Rutgers Cancer Institute and medical director of the oncology service line at RWJBarnabas Health, is senior author of the work, which appears in the February 18 online edition of Cancer. Learn more
|
|
Cancer Prevention Researcher and Leader Named President-Elect of American Society of Preventative Oncology
|
|
|
Anita Kinney, PhD, director of the Center for Cancer Health Equity at Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey, has been elected as the 2021 president-elect of the American Society of Preventive Oncology (ASPO), a multi-disciplinary society that is committed to serving as an advocate for cancer prevention and control research. Dr. Kinney, who is also associate director for Population Science and Community Outreach at Rutgers Cancer Institute, director of ScreenNJ (a statewide cancer screening program), and a professor of biostatistics and epidemiology at the Rutgers School of Public Health, will serve a two-year term prior to serving as president of the society. Learn more
|
|
Examining Surgery Delays for Renal Cell Carcinoma Patients during COVID-19
|
|
|
Researchers at Rutgers Cancer Institute of New Jersey explored the impact of surgery delays for patients with renal cell carcinoma during the COVID-19 pandemic. Arnav Srivastava, MD, MPH, Rutgers Robert Wood Johnson Medical School urology resident, along with senior author, Eric A. Singer, MD, MA, MS, FACS, associate chief of urology and urologic oncology and director of the Kidney Cancer Program at Rutgers Cancer Institute and associate professor of surgery and radiology at Rutgers Robert Wood Johnson Medical School, share more about the results presented at the virtual American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium. Learn more
|
|
Colorectal Cancer: Common Questions Answered
|
|
|
According to the American Cancer Society, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. Daniel L. Feingold, MD, FASCRS, FACS, chief of colorectal surgery in the Gastrointestinal Oncology Program at Rutgers Cancer Institute of New Jersey professor of surgery at Rutgers Robert Wood Johnson Medical School, addresses common questions about colorectal cancer including screening and detection options, treatment options and resources available.
|
|
|
|
|
|
|